. Author manuscript; available in PMC: 2018 Apr 15.

Published in final edited form as: Cancer. 2016 Nov 28;123(8):1416–1423. doi: 10.1002/cncr.30454

Table 4.

Validity testing for the Cancer and Treatment Distress (CTXD) total mean score versus the SF-36 Physical Functioning (PF) and Mental Health (MH) scales at each time point ^a

Time point / Measure	N	M (SD)	Correlation with CTXD total ^b	Correlation with SF-36 PF ^b	Correlation with CTXD total at baseline ^c
Baseline
SF-36 PF	688	68.3 (23.3)	−.337^***
SF-36 MH	688	74.6 (17.4)	−.660^***	+.297^***

100 days
CTXD	565	0.93 (0.60)			+.628^***
SF-36 PF	555	66.6 (23.9)	−.423^***		−.224^***
SF-36 MH	552	78.0 (16.9)	−.653^***	+.281^***	−.463^***

180 days
CTXD	491	0.85 (0.59)			+.617^***
SF-36 PF	485	70.7 (23.8)	−.481^***		−.260^***
SF-36 MH	484	78.8 (16.7)	−.709^***	+.372^***	−.437^***

* P <.05

** P <.01

^***

P <.001

PF and MH higher score = better function, CTXD higher score = more distress

Correlation with concurrent measures, addressing convergent (SF-36 MH) and divergent (SF-36 PF) validity

Correlation of baseline CTXD with CTXD at 100 and 180 days (partly addressing test-retest consistency) and with PF and MH at 100 and 180 days (addressing predictive validity)